Description:Lefamulin acetate is a semi-synthetic antibiotic belonging to the pleuromutilin class, primarily used for the treatment of bacterial infections, particularly those caused by Gram-positive bacteria. It functions by inhibiting protein synthesis through binding to the peptidyl transferase center of the bacterial ribosome, thereby preventing the growth and reproduction of bacteria. The acetate form of lefamulin enhances its solubility and bioavailability. This compound is characterized by its broad-spectrum activity, making it effective against various pathogens, including those resistant to other antibiotics. Lefamulin acetate is typically administered via intravenous or oral routes, depending on the formulation. Its pharmacokinetic properties include a favorable distribution profile and a relatively long half-life, allowing for convenient dosing regimens. As with any antibiotic, the potential for resistance development is a concern, necessitating careful use in clinical settings. Overall, lefamulin acetate represents a significant advancement in antibiotic therapy, particularly in the context of rising antibiotic resistance.
We use cookies to enhance your visit. We do not include advertising.
Please see our Cookies Policy for more details or adjust your preferences in "Settings".
This is the advanced settings system for our own and third-party cookies. Here you can modify parameters that will directly affect your browsing experience on this website. If you wish you may check the list of Cookie types.
Please note that disabling cookies can cause failures in the normal operation of the web.
